Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kyverna Therapeutics, Inc. (KYTX), Immunome (IMNM) and Prime Medi...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRME	$3.04	-0.65%	347.14K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRME	$3.04	-0.7%	347.14K
3
4
5
6

PRME

PRME

Dividend Overview

Get Prime Medicine Inc. Data in Excel

Get Prime Medicine Inc. Data in Excel